COX-2 expression in breast carcinoma cells was not found to be a surrogate marker of aromatase expression, and neither COX-2 nor aromatase expression in carcinoma cells predicted response to letrozole or tamoxifen treatment. The gene discussed is PTGS2; the disease is breast carcinoma.